Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

PD-L1 Expression and Clinicopathological Factors in Renal Cell Carcinoma: A Comparison of Antibody Clone 73-10 With Clone 28-8

JUNICHI IKEDA, CHISATO OHE, TAKASHI YOSHIDA, HARUYUKI OHSUGI, MOTOHIKO SUGI, KOJI TSUTA and HIDEFUMI KINOSHITA
Anticancer Research September 2021, 41 (9) 4577-4586; DOI: https://doi.org/10.21873/anticanres.15271
JUNICHI IKEDA
1Department of Pathology, Kansai Medical University Hospital, Hirakata, Japan;
2Department of Urology and Andrology, Kansai Medical University Hospital, Hirakata, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHISATO OHE
1Department of Pathology, Kansai Medical University Hospital, Hirakata, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ohec@hirakata.kmu.ac.jp
TAKASHI YOSHIDA
2Department of Urology and Andrology, Kansai Medical University Hospital, Hirakata, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HARUYUKI OHSUGI
2Department of Urology and Andrology, Kansai Medical University Hospital, Hirakata, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MOTOHIKO SUGI
2Department of Urology and Andrology, Kansai Medical University Hospital, Hirakata, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOJI TSUTA
1Department of Pathology, Kansai Medical University Hospital, Hirakata, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIDEFUMI KINOSHITA
2Department of Urology and Andrology, Kansai Medical University Hospital, Hirakata, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Expression of programmed death ligand-1 (PD-L1) is associated with poor prognosis in renal cell carcinoma (RCC). Although a new antibody clone for immunohistochemical assay, 73-10, has shown greater sensitivity than other assays (28-8, 22C3, SP142, and SP263) in non-small cell lung cancer, PD-L1 expression using 73-10 has never been assessed in RCC. Therefore, this study aimed to evaluate the association of clinicopathological factors with PD-L1 expression detected by clone 73-10 and compare it with that detected by 28-8. Patients and Methods: Tissue microarray samples from 582 patients who underwent radical or partial nephrectomy for RCC were immunohistochemically assessed using clones 73-10 and 28-8. Results: The positivity for PD-L1 expression in RCC by 73-10 was higher than that of 28-8 and significantly associated with worse pathological factors and a higher risk of cancer-specific mortality. Conclusion: Positivity for PD-L1 expression by 73-10, as compared to 28-8, was associated with worse clinicopathological factors and prognosis for patients with RCC.

Key Words:
  • PD-L1
  • 73-10
  • 28-8
  • immunohistochemistry
  • renal cell carcinoma
  • Received June 30, 2021.
  • Revision received July 25, 2021.
  • Accepted July 30, 2021.
  • Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
View Full Text

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

patientACCESS

patientACCESS - Patients desiring access to articles
PreviousNext
Back to top

In this issue

Anticancer Research: 41 (9)
Anticancer Research
Vol. 41, Issue 9
September 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
PD-L1 Expression and Clinicopathological Factors in Renal Cell Carcinoma: A Comparison of Antibody Clone 73-10 With Clone 28-8
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
3 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
PD-L1 Expression and Clinicopathological Factors in Renal Cell Carcinoma: A Comparison of Antibody Clone 73-10 With Clone 28-8
JUNICHI IKEDA, CHISATO OHE, TAKASHI YOSHIDA, HARUYUKI OHSUGI, MOTOHIKO SUGI, KOJI TSUTA, HIDEFUMI KINOSHITA
Anticancer Research Sep 2021, 41 (9) 4577-4586; DOI: 10.21873/anticanres.15271

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
PD-L1 Expression and Clinicopathological Factors in Renal Cell Carcinoma: A Comparison of Antibody Clone 73-10 With Clone 28-8
JUNICHI IKEDA, CHISATO OHE, TAKASHI YOSHIDA, HARUYUKI OHSUGI, MOTOHIKO SUGI, KOJI TSUTA, HIDEFUMI KINOSHITA
Anticancer Research Sep 2021, 41 (9) 4577-4586; DOI: 10.21873/anticanres.15271
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Primary Synovial Sarcoma of the Bone: A Case Report and Literature Review
  • Melanoma of the Lower Limbs and Hips: A Surveillance, Epidemiology, and End Results Analysis of Epidemiology and Survival 2000-2019
  • Ganglioside GD2 Expression Is Associated With Unfavorable Prognosis in Early Triple-negative Breast Cancer
Show more Clinical Studies

Similar Articles

Keywords

  • PD-L1
  • 73-10
  • 28-8
  • immunohistochemistry
  • renal cell carcinoma
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire